Suppr超能文献

组织因子途径抑制剂与凝血的修正理论。

Tissue factor pathway inhibitor and the revised theory of coagulation.

作者信息

Broze G J

机构信息

Division of Hematology, Washington University School of Medicine, Jewish Hospital, St. Louis, Missouri 63110, USA.

出版信息

Annu Rev Med. 1995;46:103-12. doi: 10.1146/annurev.med.46.1.103.

Abstract

Tissue factor pathway inhibitor (TFPI) is a multivalent, Kunitz-type plasma proteinase inhibitor that regulates tissue factor-induced coagulation. TFPI directly inhibits activated factor X and, in a factor Xa-dependent fashion, produces feedback inhibition of the factor VIIa/tissue factor catalytic complex. The properties of this rediscovered inhibitor appear, at least in part, to explain the clinical requirement for both the extrinsic and intrinsic pathways of the cascade and waterfall theories of blood clotting and have led to a reformulation of the coagulation mechanism. In the revised hypothesis, factor VIIa/tissue factor is responsible for the initiation of coagulation, but owing to TFPI-mediated inhibition, sustained hemostasis requires the persistent and amplified procoagulant action of intrinsic factors VIII, IX, and XI.

摘要

组织因子途径抑制剂(TFPI)是一种多价的Kunitz型血浆蛋白酶抑制剂,可调节组织因子诱导的凝血过程。TFPI直接抑制活化的因子X,并以因子Xa依赖的方式对因子VIIa/组织因子催化复合物产生反馈抑制。这种重新发现的抑制剂的特性似乎至少部分地解释了凝血瀑布学说中外源性和内源性凝血途径的临床需求,并导致了凝血机制的重新阐述。在修订后的假说中,因子VIIa/组织因子负责启动凝血,但由于TFPI介导的抑制作用,持续的止血需要内源性因子VIII、IX和XI持续且放大的促凝作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验